Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (formerly Microbia) is dedicated to creating, developing, and commercializing innovative human medicines, and has clinical stage programs in GI disorders and dyslipidemia. The Company discovered, developed and is commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood is also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Size (employees)
674 (est)+43%
Ironwood Pharmaceuticals is headquartered in Cambridge, US

Key People at Ironwood Pharmaceuticals

Peter Hecht

Peter Hecht

Co-Founder
Brian Cali

Brian Cali

Co-Founder and Vice President of Program Management

Ironwood Pharmaceuticals Office Locations

Ironwood Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
301 Binney St

Ironwood Pharmaceuticals Data and Metrics

Ironwood Pharmaceuticals Financial Metrics

Ironwood Pharmaceuticals's revenue was reported to be $274 m in FY, 2016 which is a 83% increase from the previous period.
USD

Revenue (FY, 2016)

274 m

Revenue growth (FY, 2015 - FY, 2016), %

83%

Net income (FY, 2016)

(81.7 m)

Market capitalization (26-Jun-2017)

2.8 b

Closing share price (26-Jun-2017)

19.6

Cash (31-Dec-2016)

54 m
Ironwood Pharmaceuticals's current market capitalization is $2.8 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

22.9 m76.4 m149.6 m274 m

Revenue growth, %

234%96%83%

Gross profit

15.7 m50.9 m149.5 m

Gross profit Margin, %

69%67%100%

Operating expense total

267.7 m220.2 m251.6 m

EBIT

(252 m)(169.4 m)(102.1 m)

EBIT margin, %

(1101%)(222%)(68%)

Net Income

(272.8 m)(189.6 m)(142.7 m)(81.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

75.5 m74.3 m261.3 m54 m

Accounts Receivable

513 k10 k2.9 m933 k

Inventories

6.2 m10.6 m6.3 m9 m

Current Assets

229.1 m289.7 m500.2 m380.2 m

PP&E

37.4 m29.8 m21.1 m20.5 m

Goodwill

785 k

Total Assets

279 m333.5 m619.1 m709.8 m

Accounts Payable

10.1 m9.8 m8.6 m17.7 m

Total Debt

175.8 m

Current Liabilities

41 m60.5 m76.5 m91.1 m

Common Stock

103 k125 k127 k133 k

Additional Paid-in Capital

815.9 m1.1 b1.2 b1.3 b

Retained Earnings

(777.8 m)(967.4 m)(1.1 b)(1.2 b)

Total Equity

38.2 m88.6 m95.1 m66.7 m

Debt to Equity Ratio

4.6 x

Debt to Assets Ratio

0.6 x

Financial Leverage

7.3 x3.8 x6.5 x10.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(272.8 m)(189.6 m)(142.7 m)(81.7 m)

Depreciation and Amortization

11.7 m12.3 m11.6 m10.3 m

Accounts Receivable

(1.7 m)(24 m)(29 m)(10 m)

Inventories

(52 k)(3.9 m)2.6 m(3.1 m)

Accounts Payable

(11.7 m)1.4 m

Cash From Operating Activities

(273.4 m)(155.6 m)(106.9 m)(25.4 m)

Purchases of PP&E

(9.6 m)(3.5 m)(4 m)(4.2 m)

Cash From Investing Activities

(101.4 m)(56.6 m)

Cash From Financing Activities

313.6 m210.9 m303.1 m(4.2 m)

Interest Paid

18.4 m19.6 m22.7 m24.5 m
Y, 2016

Financial Leverage

10.6 x

Ironwood Pharmaceuticals Market Value History

Ironwood Pharmaceuticals Median Salaries

Source: 16 public H-1B filings from Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Online and Social Media Presence

Ironwood Pharmaceuticals Company Life and Culture

You may also be interested in